Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shCREB refers to a short hairpin RNA (shRNA) construct designed to silence the expression of the cyclic AMP response element binding protein (CREB), a transcription factor that plays a critical role in cell survival, proliferation, and drug resistance. In cancers such as malignant mesothelioma (MM), CREB is often constitutively activated, driving the expression of pro-survival genes like Bcl-2 and Bcl-xL and promoting the secretion of angiogenic and inflammatory cytokines (e.g., VEGF, IL-6, IL-8). By knocking down CREB expression, shCREB attenuates tumor growth, induces apoptosis, and enhances the sensitivity of cancer cells to chemotherapeutic agents like doxorubicin. This approach is primarily utilized in preclinical research to investigate the therapeutic potential of targeting the CREB signaling pathway.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on shCREB.